At the time of writing, Beam Therapeutics Inc [BEAM] stock is trading at $30.43, down -8.18%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BEAM shares have gain 6.36% over the last week, with a monthly amount glided 15.31%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on January 29, 2025, when Cantor Fitzgerald upgraded its rating to a Overweight. Previously, Leerink Partners upgraded its rating to Outperform on November 06, 2024, and elevated its price target to $39. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $80 on July 23, 2024. JP Morgan upgraded its rating to a Overweight and raised its price target to $40 on January 29, 2024. BofA Securities downgraded its rating to Neutral for this stock on December 15, 2023, but kept the price target unchanged to $35. In a note dated December 08, 2023, Jefferies downgraded an Hold rating on this stock and revised its target price from $75 to $30.
For the past year, the stock price of Beam Therapeutics Inc fluctuated between $20.84 and $49.50. Currently, Wall Street analysts expect the stock to reach $50.5 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $30.43 at the most recent close of the market. An investor can expect a potential return of 65.95% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
According to Beam Therapeutics Inc [NASDAQ:BEAM], the company’s sales were 349.64M for trailing twelve months, which represents an -17.01% plunge. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.52%, Pretax Profit Margin comes in at -0.41%, and Net Profit Margin reading is -0.41%. To continue investigating profitability, this company’s Return on Assets is posted at -0.12, Equity is -0.16 and Total Capital is -0.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 29.11 points at the first support level, and at 27.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 32.83, and for the 2nd resistance point, it is at 35.23.
Ratios To Look Out For
It is important to note that Beam Therapeutics Inc [NASDAQ:BEAM] has a current ratio of 5.69. Further, the Quick Ratio stands at 5.69, while the Cash Ratio is 1.38. Considering the valuation of this stock, the price to sales ratio is 7.21, the price to book ratio is 3.17.
Transactions by insiders
Recent insider trading involved Cavanagh Bethany J, SVP, Finance and Treasurer, that happened on Feb 18 ’25 when 6287.0 shares were sold. Chief Legal Officer, Bellon Christine completed a deal on Feb 14 ’25 to sell 10000.0 shares. Meanwhile, Officer CHRISTINE BELLON bought 10000.0 shares on Feb 14 ’25.
